Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Group 1: Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Group 2: Financial Performance and Issues - Simulations Plus reported disappointing preliminary financial results for Q3 2025, citing market uncertainties as significant headwinds, leading to a stock price drop of over 24% [4] - The company announced a $77.2 million charge related to prior acquisitions in its Q3 2025 financial results, which contributed to a further decline in stock price of nearly 26% [5] - The dismissal of Grant Thornton LLP as the company's auditor raised concerns about internal controls and segment reporting, with the auditor identifying unresolved issues [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls, but evidence suggests struggles with integration and control effectiveness [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2] - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3] Financial Performance and Issues - Simulations Plus claimed effective internal controls over financial reporting, but evidence suggests struggles with the integration of Pro-ficiency and ineffective internal controls [3] - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4] - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5] Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5]

Core Viewpoint - Simulations Plus, Inc. is under investigation for potential violations of federal securities laws following disappointing financial results and issues related to its acquisition of Pro-ficiency Holdings, Inc. [1][2][3] Company Overview - Simulations Plus is a software company focused on modeling and simulation tools for the pharmaceutical, biotechnology, and chemical industries [2]. - The company acquired Pro-ficiency Holdings, Inc. in June 2024, aiming to double its total addressable market and enhance sales [2][3]. Financial Performance and Issues - Simulations Plus claimed successful integration of Pro-ficiency and effective internal controls over financial reporting, which appears to be misleading as the company struggled with integration and lacked effective controls [3]. - On June 11, 2025, the company announced disappointing preliminary financial results for Q3 2025, attributing challenges to market uncertainties, leading to a stock price drop of over 24% [4]. - The Q3 2025 financial results included a $77.2 million charge related to prior acquisitions, and the company dismissed its auditor Grant Thornton, citing unresolved matters regarding segment reporting and internal controls [5]. Stock Market Reaction - Following the announcement of the impairment charge and auditor dismissal, Simulations Plus's stock fell nearly 26% from $17.47 to $12.97 per share [5].

Core Viewpoint - Nutex Health Inc. has appointed Grant Thornton LLP as its new independent registered public accounting firm, replacing CBIZ CPAs, effective May 15, 2025, as part of a commitment to corporate governance and following a careful evaluation process [1][3]. Company Overview - Nutex Health Inc. is a physician-led integrated healthcare delivery system with 24 micro hospitals and hospital outpatient departments across 11 states, focusing on primary care-centric, risk-bearing physician networks [1][4]. - The company operates two divisions: a Hospital Division that manages innovative healthcare models, including micro-hospitals and specialty hospitals, and a Population Health Management Division that oversees provider networks such as Independent Physician Associations (IPAs) [4][5]. Auditor Transition - The decision to change auditors was not due to any disagreements regarding accounting principles, financial statement disclosures, or auditing procedures between Nutex Health and CBIZ [2]. - The transition to Grant Thornton is intended to be seamless, with both firms collaborating closely during the process [2]. Management Commentary - The Chief Financial Officer of Nutex Health expressed that the change in auditors aligns with the company's growth momentum and commitment to best corporate governance practices, thanking CBIZ for their past services [3].

Financial Data and Key Metrics Changes - The company reported a total of 107,352,634 shares of common stock outstanding as of the record date [4] - Approximately 93% of shares voted for the election of directors, indicating strong shareholder support [17] - The ratification of Grant Thornton LLP as the independent registered public accounting firm for 2025 received approximately 99% approval [17] - The approval of executive compensation was supported by approximately 94% of shares [17] - The amendment to increase the number of authorized shares of common stock received approximately 98% approval [17] Business Line Data and Key Metrics Changes - No specific data on individual business lines was provided in the meeting Market Data and Key Metrics Changes - No specific market data was discussed during the meeting Company Strategy and Development Direction and Industry Competition - The company is focused on enhancing stockholder access and participation through a virtual meeting format, indicating a commitment to transparency and communication [3] - The increase in authorized shares suggests potential plans for future growth and capital raising [13] Management's Comments on Operating Environment and Future Outlook - No specific comments from management regarding the operating environment or future outlook were provided in the meeting Other Important Information - The meeting was conducted virtually to enhance stockholder access [3] - The results of the voting will be filed in a Form 8-K within four business days [18] Q&A Session Summary Question: Were there any questions regarding the nominations for directors? - No specific questions were recorded regarding the nominations [10] Question: Were there any questions regarding the ratification of Grant Thornton LLP? - No specific questions were recorded regarding the ratification [11] Question: Were there any questions on the proposal for executive compensation? - No specific questions were recorded regarding the executive compensation proposal [12] Question: Were there any questions on the amendment to increase authorized shares? - No specific questions were recorded regarding the amendment [15]